Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome

References

Page 1

	Year	Citations
Everolimus for Advanced Pancreatic Neuroendocrine Tumors James C. Yao, Manisha H. Shah, Tetsuhide Ito, New England Journal of Medicine	2011	2.8K
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, New England Journal of Medicine	2011	2.5K
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger, Journal of Clinical Oncology	2009	2.5K
Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome Joseph Rubin, Jaffer A. Ajani, William J. Schirmer, Journal of Clinical Oncology	1999	387
Population-Based Study of Islet Cell Carcinoma James C. Yao, Milton P. Eisner, Colleen Leary, Annals of Surgical Oncology	2007	337
The Glucagonoma Syndrome Clinical and Pathologic Features in 21 Patients Robert A. Wermers, Vahab Fatourechi, Alan Wynne, Medicine	1996	315
Pancreatic neuroendocrine tumors Joshua S. Hill, James T. McPhee, Theodore P. McDade, Cancer	2009	293
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors Jeffrey A. Norton Archives of Surgery	2003	218
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours Ettore Seregni, L. Ferrari, Emilio Bajetta, Annals of Oncology Neuroendocrine DisorderPathologyAdrenal DiseaseNeuroendocrine TumorsMedicine	2001	150
Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour Roy Eldor, Benjamin Gläser, Merav Fraenkel, Clinical Endocrinology	2011	131

Page 1